Description
Badges:
- HPLC/MS Verified
- QR-linked COA per batch
- Secure Payments (Card + Crypto)
- Fast Canada Shipping
🔬 Science & Mechanism
PT-141 is a melanocortin receptor agonist derived from melanotan II.
- Activates MC3R and MC4R receptors in the brain.
- Enhances dopamine signaling linked to sexual desire and arousal.
- Unlike Viagra, which works on blood flow, PT-141 works on sexual motivation centers in the CNS.
📊 Clinical Evidence
- FDA-approved (2019) for female sexual dysfunction (HSDD) under the brand Vyleesi.
- Clinical trials: Increased sexual desire and satisfaction in women with hypoactive desire disorder.
- In men, shown to improve arousal and erectile function even in non-responders to PDE5 inhibitors.
💉 Dosing Guide (Educational)
Reported Protocols:
- Subcutaneous injection: 1–2 mg, as needed, ~30–60 minutes before intimacy.
- Some users report effects lasting up to 24–36 hours.
- Start low (0.5–1 mg) to assess tolerance.
💧 Reconstitution (10 mg vial + 2 mL BAC water)
- Final concentration = 5 mg/mL
- On insulin syringe (100 units = 1 mL): 50 mcg per unit
| Desired Dose |
Volume (mL) |
Syringe Units |
| 0.5 mg |
0.10 mL |
10 units |
| 1.0 mg |
0.20 mL |
20 units |
| 1.5 mg |
0.30 mL |
30 units |
| 2.0 mg |
0.40 mL |
40 units |
🧊 Storage
- Store lyophilized vial refrigerated (2–8 °C).
- After reconstitution, refrigerate and use within 30 days.
- Protect from light.
❓ FAQ
How is PT-141 different from Viagra or Cialis?
PT-141 acts in the brain to increase sexual desire, while PDE5 inhibitors work only on blood flow.
Can women use PT-141?
Yes — PT-141 (Vyleesi) is FDA-approved specifically for female sexual dysfunction.
How quickly does it work?
Typically within 30–60 minutes, with effects lasting up to 24 hours.
⚠️ Disclaimer
- For educational purposes only.
- Not FDA or Health Canada approved outside specific indications.
- Customers assume responsibility for safe handling.
📚 References
- Kingsberg SA, et al. Bremelanotide for female hypoactive sexual desire disorder: phase 3 RECONNECT trials. J Sex Med. 2019.
🔗 https://pubmed.ncbi.nlm.nih.gov/31351961/
- FDA Approval: Vyleesi (Bremelanotide) for HSDD. 2019.
🔗 https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-low-sexual-desire-women
- Wessells H, et al. Bremelanotide for male erectile dysfunction: clinical evidence. Urology. 2000.
🔗 https://pubmed.ncbi.nlm.nih.gov/10840092/
- Shadiack AM, et al. Melanocortin receptor agonists and sexual arousal pathways. J Pharmacol Exp Ther. 2007.
🔗 https://pubmed.ncbi.nlm.nih.gov/17475905/
Reviews
There are no reviews yet.